Dr. Jeffrey Weber of NYU Langone Health recently reported in Targeted Oncology that three year-data from the phase II CheckMate 238 clinical trial reveal that nivolumab (Opdivo) shows superiority over ipilimumab (Yervoy) in patients with resected stage III or IV melanoma based on research presented to those attending the 2019 European Society for Medical Oncology (ESMO) Congress.
Dr. Weber reports that the relapse-free survival (RFS) rate in Opdivo at 58% was considerably higher than Yervoy at 45%. Moreover, Opdivo outperformed Yervoy in terms of distant metastases-free survival (DMFS) with an HR of 0.78.
During the study, multiple subgroups were analyzed, reported by Targeted Oncology. All groups (except those with stage IV melanoma) experienced better results with Opdivo in terms of both RFS and DMFS. Those in the study with stage IV melanoma experienced better results from Opdivo vs. Yervoy.
The Checkmate 238 study was a Phase III study, including over 1,200 patients. The purpose of this study was to determine whether not nivolumab is better than ipilimumab to prevent the recurrence of melanoma. About 136 research sites and centers participated in this effort.
Follow the link to the source to read the interview with deputy director Perlmutter Cancer Center, NYU Langone Health.
What is Opdivo?
The drug was discovered at Medarex and developed by that firm and Ono Pharmaceutical. Bristol-Myers Squibb commercialized it. The treatment was invested by Dr. Changyu Wang and his team of scientists at Medarex using their transgenic mice with a humanized immune system.